This article has been cited by the following publications. This list is generated based on data provided by
Du, Xianglin L.
Parikh, Rohan C.
Lairson, David R.
Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007–2010 after the 2006 introduction of bevacizumab.
Leonardo Alves, T.
De Boer, A.
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
Annals of Oncology,
Connell, Cathleen M.
De Vries, Raymond G.
Janz, Nancy K.
Bickel, Kathleen E.
Silveira, Maria J.
Paradox of Prescribing Late Chemotherapy: Oncologists Explain.
Journal of Oncology Practice,
Hoch, Jeffrey S.
Chan, Kelvin K.W.
The right amount of chemotherapy in non-curable disease: Insights from health economics.
Journal of Cancer Policy,
van Exel, Job
B.F. Brouwer, Werner
Priority to End of Life Treatments? Views of the Public in the Netherlands.
Value in Health,
Joshua, Anthony M.
Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer.
Urologic Oncology: Seminars and Original Investigations,
Vermeulen, Karin M.
Krabbe, Paul F. M.
Value judgment of health interventions from different perspectives: arguments and criteria.
Cost Effectiveness and Resource Allocation,
Mind the gap: Investigating the role of collective action in the evolution of Indian medical device regulation.
Technology in Society,
Solberg, Carl Tollef
Severity as a Priority Setting Criterion: Setting a Challenging Research Agenda.
Health Care Analysis,
Morrison, R. Sean
Economics of Palliative Care for Cancer: Interpreting Current Evidence, Mapping Future Priorities for Research.
Journal of Clinical Oncology,
Public values and plurality in health priority setting: What to do when people disagree and why we should care about reasons as well as choices.
Social Science & Medicine,